18F-fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 9, 2011, Pages 1773-1783

  Ohira, Hiroshi ^a   Tsujino, Ichizo ^a   Yoshinaga, Keiichiro ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

18F fluoro 2 deoxyglucose positron emission tomography; Cardiac sarcoidosis; Fasting; Heparin; Low carbohydrate diet; Magnetic resonance imaging

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201; DIAGNOSTIC AGENT;

CARDIAC SARCOIDOSIS; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DIET RESTRICTION; DIET THERAPY; DISEASE ACTIVITY; HEART MUSCLE; HEART SCINTISCANNING; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LIPID DIET; LOW CARBOHYDRATE DIET; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN DIET; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; CARDIOMYOPATHY; METABOLISM; METHODOLOGY; SCINTISCANNING;

ADRENAL CORTEX HORMONES; CARDIOMYOPATHIES; FLUORODEOXYGLUCOSE F18; HUMANS; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; SARCOIDOSIS;

EID: 80455174061     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1832-y     Document Type: Review

References (72)

1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-34. (Pubitemid 27183653)
2. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993;103:253-8. (Pubitemid 23027268)
3. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11. (Pubitemid 9092005)
4. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976;278:455-69.
5. Lorell B, Alderman EL, Mason JW. Cardiac sarcoidosis. Diagnosis with endomyocardial biopsy and treatment with corticosteroids. Am J Cardiol 1978;42:143-6. (Pubitemid 8387798)
6. Ishikawa T, Kondoh H, Nakagawa S, Koiwaya Y, Tanaka K. Steroid therapy in cardiac sarcoidosis. Increased left ventricular contractility concomitant with electrocardiographic improvement after prednisolone. Chest 1984;85:445-7. (Pubitemid 14160392)
7. Hiraga H, Hiroe M, Iwai K. Guidelines for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases (in Japanese). Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23-4.
8. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with (13) N-NH (3)/(18) F-FDG PET. J Nucl Med 2003;44:1030-6. (Pubitemid 39663376)
9. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98. (Pubitemid 47611626)
10. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43. (Pubitemid 41373496)
11. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.
12. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.
13. Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002;105:1144-5. (Pubitemid 34212627)
14. Tadamura E, Yamamuro M, Kubo S, Kanao S, Hosokawa R, Kimura T, et al. Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation 2006;113:e771-3. (Pubitemid 43948038)
15. Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: A call for prospective studies of newer imaging techniques. Eur Respir J 2007;29:418-22. (Pubitemid 46231921)
16. Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977;63:86-108. (Pubitemid 8146656)
17. Bleeker-Rovers CP, Vos FJ, Mudde AH, Dofferhoff AS, de Geus-Oei LF, Rijnders AJ, et al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 2007;34:694-703. (Pubitemid 46669364)
18. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation 2007;116:1052-61. (Pubitemid 47329570)
19. Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994;21:297-305. (Pubitemid 24106447)
20. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-9.
21. Warshauer DM, Lee JK. Imaging manifestations of abdominal sarcoidosis. AJR Am J Roentgenol 2004;182:15-28. (Pubitemid 38017713)
22. Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:234-5.
23. Smedema JP, Reenaers V, Geukens R. Images in cardiology. Cardiac sarcoidosis in a 60 year old woman. Heart 2006;92:688.
24. Wu YW, Tadamura E, Yamamuro M, Kanao S, Hosokawa R, Kimura T, et al. Complementary appearance of glucose and lipid metabolism in cardiac sarcoidosis. Int J Cardiol 2007;116:281-3. (Pubitemid 46241495)
25. Nomura S, Funabashi N, Tsubura M, Uehara M, Shiina Y, Daimon M, et al. Cardiac sarcoidosis evaluated by multimodality imaging. Int J Cardiol. In press 2010.
26. Bartlett ML, Bacharach SL, Voipio-Pulkki LM, Dilsizian V. Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects. J Nucl Med 1995;36:188-95.
27. Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31:1749-56. (Pubitemid 20374504)
28. Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F]fluoro-D-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002;4:232-7. (Pubitemid 34705226)
29. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008;190:W151-6.
30. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563-8.
31. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010;17:286-91.
32. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 1987;79:359-66. (Pubitemid 17009666)
33. Yoshinaga K, Tamaki N. Imaging myocardial metabolism. Curr Opin Biotechnol 2007;18:52-9. (Pubitemid 46227966)
34. Choi Y, Brunken RC, Hawkins RA, Huang SC, Buxton DB, Hoh CK, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med 1993;20:308-18. (Pubitemid 23234002)
35. Lum D, Wandell S, Ko J, Coel M. 1. Positron emission tomography of thoracic malignancies. Reduction of myocardial fluorodeoxyglucose uptake artifacts with a carbohydrate restricted diet. Clin Positron Imaging 2000;3:155.
36. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teräs M, Haaparanta M, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767-74.
37. Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand Suppl 1988;724:1-56.
38. Blockmans D. The use of (18F) fluoro-deoxyglucose positron emission tomography in the assessment of large vessel vasculitis. Clin Exp Rheumatol 2003;21:S15-22. (Pubitemid 38016475)
39. Nuutila P, Knuuti MJ, Raitakari M, Ruotsalainen U, Teräs M, Voipio-Pulkki LM, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol 1994;267:E941-6.
40. Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography: an autopsy case. Circulation 2010;122:535-6.
41. Kaminaga T, Takeshita T, Yamauchi T, Kawamura H, Yasuda M. The role of iodine-123-labeled 15-(p-iodophenyl)-3R, S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis. Int J Cardiol 2004;94:99-103. (Pubitemid 38314695)
42. Ohira H, Tsujino I, Sato T, Yoshinaga K, Manabe O, Oyama N, et al. Early detection of cardiac sarcoid lesions with 18F-fluoro-2-deoxyglucose positron emission tomography. Intern Med. In press 2011.
43. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002;32:293-321. (Pubitemid 35332975)
44. Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 2006;7:57-69.
45. Matsuki M, Matsuo M. MR findings of myocardial sarcoidosis. Clin Radiol 2000;55:323-5. (Pubitemid 32054524)
46. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadoliniumenhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90. (Pubitemid 40704507)
47. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001;110:520-7.
48. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol 2005;184:249-54. (Pubitemid 40040938)
49. Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: A 1-year follow-up study. Chest 2002;122:1895-901. (Pubitemid 36051121)
50. Serra JJ, Monte GU, Mello ES, Coral GP, Avila LF, Parga JR, et al. Images in cardiovascular medicine. Cardiac sarcoidosis evaluated by delayed-enhanced magnetic resonance imaging. Circulation 2003;107:e188-9.
51. Matoh F, Satoh H, Shiraki K, Odagiri K, Saitoh T, Urushida T, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol 2008;51:179-88. (Pubitemid 351718494)
52. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
53. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35. (Pubitemid 351893001)
54. Casset-Senon D, Philippe L, Renard JP, Cosnay P. Recurrent ventricular tachycardia in cardiac sarcoidosis: usefulness of fluorodeoxyglucose positron emission tomography for adequate management of corticoid therapy after placement of an implantable cardioverter defibrillator. J Nucl Cardiol 2008;15:282-5. (Pubitemid 351409244)
55. Györik S, Ceriani L, Menafoglio A, Gallino A, Wyttenbach R. 18F-FDG PET scan as follow-up tool for sarcoidosis with symptomatic cardiac conduction disturbances requiring a pacemaker. Thorax 2007;62:560. (Pubitemid 46910144)
56. Thompson RC, Cullom SJ. Issues regarding radiation dosage of cardiac nuclear and radiography procedures. J Nucl Cardiol 2006;13:19-23. (Pubitemid 43192725)
57. Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995;107:330-4.
58. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003;42:1318-33. (Pubitemid 37188362)
59. Nakazawa A, Ikeda K, Ito Y, Iwase M, Sato K, Ueda R, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photonemission CT scanning in the diagnosis of cardiac sarcoidosis. Chest 2004;126:1372-6. (Pubitemid 39391275)
60. Kiuchi S, Teraoka K, Koizumi K, Takazawa K, Yamashina A. Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging 2007;23:237-41. (Pubitemid 46431549)
61. Tadamura E, Yamamuro M, Kubo S, Kanao S, Saga T, Harada M, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 2005;185:110-5.
62. Machac J, Bacharach SL, Bateman TM, Bax JJ, Beanlands R, Bengel F, et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol 2006;13:e121-51. (Pubitemid 44913647)
63. Yoshinaga K, Klein R, Tamaki N. Generator-produced rubidium-82 positron emission tomography myocardial perfusion imagingfrom basic aspects to clinical applications. J Cardiol 2010;55:163-73.
64. Yoshinaga K, Manabe O, Tamaki N. Which imaging modality is the best for evaluation of myocardial ischemia? Physiological assessment of myocardial perfusion using nuclear cardiology would enhance coronary artery disease patient care-nuclear cardiology revisited: it's not the end of an era, just the beginning of a new era. Circ J 2011;75:713-22.
65. Tellier P, Paycha F, Antony I, Nitenberg A, Valeyre D, Foult JM, et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med 1988;85:189-93.
66. Eguchi M, Tsuchihashi K, Hotta D, Hashimoto A, Sasao H, Yuda S, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000;94:193-9. (Pubitemid 32250150)
67. Le Guludec D, Menad F, Faraggi M, Weinmann P, Battesti JP, Valeyre D. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest 1994;106:1675-82. (Pubitemid 24375125)
68. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42. (Pubitemid 34262671)
69. Smulders NM, Bast A, van Kroonenburgh MJ, Drent M. Improvement of cardiac sympathetic nerve function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2008;25:140-2.
70. Hoitsma E, Faber CG, van Kroonenburgh MJ, Gorgels AP, Halders SG, Heidendal GA, et al. Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:43-50. (Pubitemid 40444733)
71. Hyodo E, Hozumi T, Takemoto Y, Watanabe H, Muro T, Yamagishi H, et al. Early detection of cardiac involvement in patients with sarcoidosis by a non-invasive method with ultrasonic tissue characterisation. Heart 2004;90:1275-80. (Pubitemid 39433985)
72. Smedema JP. Tissue Doppler imaging in cardiac sarcoidosis. Eur J Echocardiogr 2008;9:579-80. (Pubitemid 351882116)